The advanced data analytics provider IBM Watson Health has signed its first big pharma partner, Pfizer Inc., for a new computational tool called Watson for Drug Discovery. Pfizer will use Watson’s new cloud-based data analytics tool to discover new drugs faster in the area of immuno-oncology, with a focus on discovery of new and unexplored drug targets, potential combination therapies and patient selection strategies.
Watson Health And Pfizer Partner To Harness Big Data For Drug Discovery
The advanced data analytics provider IBM Watson Health has signed its first big pharma partner – Pfizer – for a new drug discovery tool, with a focus on immuno-oncology.
More from Immuno-oncology
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
Increasingly focused on maximizing and accelerating the progress of its PD-L1 x VEGF inhibitor BNT357, the company expects new partnerships to be announced this year.
• By
Sun is acquiring Checkpoint Therapeutics, opening up opportunities to build out its strategy in the onco-derm segment with the US firm’s FDA-approved anti-PD-L1 mAb.
More from Anticancer
• By
Servier takes a Phase I rationally designed cancer candidate for $70m up front, while Black Diamond will wait on more mature data for its Phase II lead candidate in lung cancer.
• By
Deal Snapshot: The antibody-drug conjugate field continues one of the hottest dealmaking spaces and Roche continues to invest heavily. Its latest pact could be transformative for the UK firm which already has a decent number of big pharma partners.
• By
The acquisition is worth up to $1bn and adds to AstraZeneca’s broad array of cell therapy technologies.